Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

Immune checkpoint blockade is associated with endocrine-related adverse events. Thyroid dysfunction during pembrolizumab therapy, an anti-programmed cell death 1 (PD-1) receptor monoclonal antibody, remains to be fully characterized. To assess the incidence and characteristics of pembrolizumab-associated thyroid dysfunction. Thyroid function was monitored prospectively in melanoma patients who initiated pembrolizumab within an expanded access...